The lawsuit, titled Cheng v. Erasca, Inc., alleges that the company and its executive officers violated the Securities Exchange Act of 1934 by concealing critical risks associated with ERAS-0015, a pan-RAS molecular glue. According to the complaint, the company’s preclinical data relied on improper comparisons to Revolution Medicines, Inc., potentially infringing on patent and trade secret protections. These concerns surfaced on April 27, 2026, when the firm disclosed a letter from Revolution Medicines regarding alleged infringement, causing Erasca shares to drop nearly 11%.
In section Releases
Investors Face August Deadline in Erasca Securities Class Action
Investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, have until August 10 to seek appointment as lead plaintiff in a class action lawsuit. The litigation, filed in the Southern District of California, accuses the oncology company of misleading shareholders regarding its drug development.
Further market volatility followed the announcement of preliminary Phase I clinical data, which revealed a patient death and clarified that previous product comparisons were based on limited cross-study analyses rather than head-to-head trials. Following these revelations, the company's stock price declined by more than 48%. Robbins Geller Rudman & Dowd LLP is representing the class, urging investors who suffered significant losses during the specified period to contact attorneys Ken Dolitsky or Michael Albert to participate in the legal action.
Comments (0)
No comments yet. Be the first!